Meet HiFiBiO's Timothy Miller at this year’s Pharma Partnering Summit on May 14th – 15th in San Diego, CA. Looking forward to connect and collaborate with fellow biotech and pharma leaders! #PharmaPartneringSummit #partnership #innovation
HiFiBiO Therapeutics’ Post
More Relevant Posts
-
🌊✨ An enlightening and insightful Panel discussion unfolded at the 20th BioPharma Clinical Trials Nexus, as esteemed leaders explored the topic 'Small Biotech Companies in Turbulent Waters: Keys to Success and Lessons from Big Pharma's Experience'. 🌟 Its an honor to have such esteemed leaders share their wisdom, expertise, and experiences, making it a truly enlightening and enriching experience for all attendees. 📦Thank you for your valuable insights! #Smallbiotech #PharmaLeaders #Clinicaltrials #Patientengagement #LargePharma #Procurementdirect #NexusConference #Pharmacompanies #BioPharmaNexus #MedicalDirector #SanDiego #USconference
To view or add a comment, sign in
-
We just wrapped up our speaker prep for the October 9th Life Sciences Roundtable, and it's going to be a game-changer! 🔥 Our expert panel – Kathleen Brunner of Acumen Analytics, Tom Evegan of RSM US LLP, Matthew L. Fedowitz of Buchanan Ingersoll & Rooney PC, and Brian Winne of RSM US LLP – are diving into the latest strategies on: ✅ Leveraging the IP cliff to make your company a prime M&A target ✅ Mastering the “patent dance” with a practical how-to guide ✅ Evergreen tactics for your IP across small molecules, biologics, and drug/device combos This isn’t your typical IP discussion – it’s packed with actionable insights. Don’t miss out - secure your space at https://bit.ly/3LxcUTe Thank you to sponsor RSM US LLP! #LifeSciences #IPstrategy #Biotech #Innovation #PatentStrategy
To view or add a comment, sign in
-
🚀 What pharma wants: The industry's dealmakers look ahead at 2024 🚀 Were you able to attend today's #jpm2024, if not, check out these insights. As we venture into 2024, the pharmaceutical industry is at a pivotal junction, blending scientific discovery with strategic foresight. This year, it's not just about what we're developing, but how we're innovating through collaborations and partnerships. We must dive deep into the science (not finances), prioritizing patient-centric solutions, and aligning our visions to drive transformative outcomes. Let's connect, collaborate, and create a future where healthcare innovation isn't just a goal, but a reality. Remember, most deals start as collaborations. Resiliency is required and you have to play the long game. An incredible presentation and insight into this was presented at JPM Healthcare today by: Glenn Hunzinger Rachna Khosla James Sabry Devang Bhuva John Carroll #InnovateHealthcare #FutureOfHealthcare #innovation #PharmaPartnerships
To view or add a comment, sign in
-
TriRadial Solutions, Managing Director VendorSight360 - Selection & Partnerships in the Biotech, Biopharma, Medical Device space
How can you optimize your CRO relationship? If you are in North Carolina on May 21st, come to the TriRadial Navigation Forum to explore this and other trends in clinical outsourcing! #TriRadial #NavigatingGrowth #ClinicalOutsourcing
Wondering how to optimize CRO partnerships regardless of your company’s size? During our upcoming Navigation Forum moderated by Paula Brown Stafford and Julia Love, we’ll start our roundtable discussions with the latest trends and strategies to maximize CRO relationships for emerging biopharma companies. We’ll cover CRO partnerships, the increase in other third-party vendors, and corresponding technology innovations – with perspectives from small biotech, large pharma, and CROs. Our goal is to help you navigate this complex landscape and the forum’s roundtable format provides an environment that promotes collaboration and an open exchange of ideas. Forum hosted by TriRadial Solutions, 2-5pm EST Happy Hour sponsored by Habergeon LLC, 5-6pm EST We’d love to see you there! Register now to connect with industry leaders and gain the insights you need to chart your course with confidence. REGISTER with [email protected] Visit https://lnkd.in/g7ziyrrn for more information. #TriRadial #lifesciences #consulting #growth #clinicaloutsourcing #clinicaltrials #CROselection #NC #RTP
To view or add a comment, sign in
-
management is key, cross-collaboration and alignment on vision is critical to a good deal!
🚀 What pharma wants: The industry's dealmakers look ahead at 2024 🚀 Were you able to attend today's #jpm2024, if not, check out these insights. As we venture into 2024, the pharmaceutical industry is at a pivotal junction, blending scientific discovery with strategic foresight. This year, it's not just about what we're developing, but how we're innovating through collaborations and partnerships. We must dive deep into the science (not finances), prioritizing patient-centric solutions, and aligning our visions to drive transformative outcomes. Let's connect, collaborate, and create a future where healthcare innovation isn't just a goal, but a reality. Remember, most deals start as collaborations. Resiliency is required and you have to play the long game. An incredible presentation and insight into this was presented at JPM Healthcare today by: Glenn Hunzinger Rachna Khosla James Sabry Devang Bhuva John Carroll #InnovateHealthcare #FutureOfHealthcare #innovation #PharmaPartnerships
To view or add a comment, sign in
-
Fantastic article by HELIO’s Chris Cobourn. If you’re an emerging life sciences company that needs guidance on your launch and Govermment Programs participation, operational requirements and implications - HELIO is here to help!
We are getting closer and closer to the Informa Connect MDRP Summit that runs September 23rd to 25th in Chicago! With that in mind, we wanted to continue our Government Programs (GP) posting with a new white paper written by our very own Chris Cobourn on "GP Participation for Emerging Pharma & Biotech." A reminder that Chris will be speaking alongside William Sarraille and Marijo Bustos on September 25th (https://lnkd.in/exgbqVnz) The HELIO team specializes in GP, Transparency and all Compliance considerations for companies of every size, including and especially those launching their very first product. This insightful read will give you a sense of our ability to deftly steer and advise your company through this critical timeframe. Please reach out to Steven Moore at [email protected] - even if for just a conversation on how we can help. Finally - HELIO has one more surprise announcement coming ahead of the MDRP conference next week... Stay tuned!!! ;-)
To view or add a comment, sign in
-
In 2023, Massachusetts-based biopharma companies hauled in $7.67 billion in venture capital funding, according to data compiled in the Biopharma Funding and Pipeline Report published today by MassBio. This funding, which was good for 4th all-time and 31% of all national funding, went to 221 companies across 242 rounds. While only two Massachusetts biotechs went public, 38 local companies were acquired to the tune of $13.04 billion. Despite a down year for funding, the local industry has continued to make headlines for getting into the clinic, positive trial results, and FDA approvals, proving their resiliency in the face of headwinds and in taking on some of the most vexing health care challenges. Dive into all the numbers in the full report: https://lnkd.in/evCpuxsC. #biotech #biopharma #venturecapital
2023 Biopharma Funding & Pipeline Report - MassBio
https://www.massbio.org
To view or add a comment, sign in
-
In late 2023, Open Pharma co-founders Chris Winchester (CEO of Oxford PharmaGenesis) and Christopher Rains (Head of CPR BioPharma Consulting) sat down to take a retrospective look at the founding of Open Pharma and to discuss their visions for the future of #PharmaCommunications. Watch the full discussion now on the Open Pharma YouTube channel.
Insights from founders: the vision of Open Pharma
https://www.youtube.com/
To view or add a comment, sign in
-
Looking forward to attending the Biopharma & Life Sciences Connected Live Conference next week. There is a great line-up of speakers throughout the day and interesting topics will be discussed. What are the challenges and trends that we will see in the future of Biopharma? #InnoGlobal #BiopharmaLifeScience #Innovation #Manufacturing #Conference
🔬 Join us at the Main Stage of the Biopharma & Life Sciences Conference & Exhibition on January 25th! We're excited to present a critical panel discussion: "Shaping the Future: Dynamic Trends and Challenges in Ireland's Biopharma Manufacturing Sphere." Our distinguished speakers: - Ian Jones, Founder & President, InnoGlobal Digitalisation, Sustainability & Skills Solutions - Vikram Kunnath, Technology Consulting Partner, EY - Paul McCabe, Chief Operating Officer, VLE Therapeutics - John O'Brien, Head of Engineering, BioMarin Pharmaceutical Inc. Moderated by Matt Moran, Consultant and previously of BioPharmaChem Ireland and Ibec, this discussion will delve into the evolving trends and challenges reshaping Ireland's Biopharma Manufacturing landscape, offering insights from industry leaders at the forefront of innovation. 🗓️ Date: January 25th 📍 Venue: Radisson Blu Hotel & Spa Cork 🌟 Don't miss this opportunity to gain crucial perspectives on the future of Biopharma Manufacturing in Ireland! Register now to secure your spot: https://shorturl.at/rJPV5 #BioPharmaLive #Manufacturing #Innovation #Biopharma #LifeSciences #Conference
To view or add a comment, sign in
-
Creating high-performing strategic partnerships with Pharma & Biotech organisations, and delivering innovative solutions that have a positive impact on commercial and patient outcomes.
Ahead of BIO-Europe, our In Vivo journalists have explored some of the biggest deals and trends that have already shaped the start of 2024. Read on as we discuss what big pharma is looking for in strategic partners, who really were the biggest deal makers of 2023, what private equity and VC have been investing in, and why new company creation has slowed down. https://lnkd.in/g9xKcFWG
BIO-Europe Spring Digital Bag | Citeline
citeline.com
To view or add a comment, sign in
8,438 followers